endo-tert-butyl 3-[(2-nitrophenyl)amino]-8-azabicyclo[3.2.1]octane-8-carboxylate | 280762-06-3

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 托烷生物碱
• 英文名称: endo-tert-butyl 3-[(2-nitrophenyl)amino]-8-azabicyclo[3.2.1]octane-8-carboxylate
• CAS: 280762-06-3
• 化学式: C₁₈H₂₅N₃O₄
• 分子量: 347.414
• InChiKey: PLNVWLXPLJYHFB-BTTYYORXSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.94
• 重原子数：
  25.0
• 可旋转键数：
  3.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.61
• 拓扑面积：
  84.71
• 氢给体数：
  1.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  endo-tert-butyl 3-[(2-nitrophenyl)amino]-8-azabicyclo[3.2.1]octane-8-carboxylate 在 palladium 10% on activated carbon 氢气 作用下， 以 乙醇 、 乙酸乙酯 为溶剂， 反应 24.0h， 以86%的产率得到endo-tert-butyl 3-[(2-aminophenyl)amino]-8-azabicyclo[3.2.1]octane-8-carboxylate
  参考文献：
  名称：

  [EN] PIPERIDINE DERIVATIVES AS CCR5 ANTAGONISTS
  [FR] ANTAGONISTES DE CCR5 UTILES COMME AGENTS THERAPEUTIQUES

  摘要：

  公开号：

  WO2004054974A3
• 作为产物：
  描述：

  1,1-dimethylethyl endo-3-[(phenylmethyl)amino]-8-azabicyclo[3.2.1]octane-8-carboxylate 在 palladium 10% on activated carbon 、 氢气 、 N,N-二异丙基乙胺 作用下， 以 N-甲基吡咯烷酮 、 甲醇 为溶剂， 反应 16.0h， 生成 endo-tert-butyl 3-[(2-nitrophenyl)amino]-8-azabicyclo[3.2.1]octane-8-carboxylate
  参考文献：
  名称：

  Novel 4,4-Disubstituted Piperidine-Based C–C Chemokine Receptor-5 Inhibitors with High Potency against Human Immunodeficiency Virus-1 and an Improved human Ether-a-go-go Related Gene (hERG) Profile

  摘要：

  We recently described (J. Med. Chem. 2008, 51, 6538-6546) a novel class of CCR5 antagonists with strong anti-HIV potency. Herein, we detail SAR converting leads 1 and 2 to druglike molecules. The pivotal structural motif enabling this transition was the secondary sulfonamide substituent. Further fine-tuning of the substituent pattern in the sulfonamide paved the way to enhancing potency and bioavailability and minimizing hERG inhibition, resulting in discovery of clinical compound 122 (GSK163929).

  DOI：

  10.1021/jm200279v

文献信息

• Substituted-Quinoxaline-Type Piperidine Compounds and the Uses Thereof
  申请人：FUCHINO Kouki

  公开号：US20100216726A1

  公开（公告）日：2010-08-26

  The invention relates to Substituted-Quinoxaline-Type Piperidine Compounds, compositions comprising an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound.

  本发明涉及取代喹喔啉型哌啶化合物、包含有效量取代喹喔啉型哌啶化合物的组合物以及治疗或预防某种疾病（如疼痛）的方法，包括向需要治疗的动物施用有效量取代喹喔啉型哌啶化合物。
• SUBSTITUTED-QUINOXALINE-TYPE PIPERIDINE COMPOUNDS AND THE USES THEREOF
  申请人：Purdue Pharma L.P.

  公开号：US20150141643A1

  公开（公告）日：2015-05-21

  The invention relates to Substituted-Quinoxaline-Type Piperidine Compounds, compositions comprising an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound.

  该发明涉及取代喹喔啉型哌啶化合物，包括一种有效量的取代喹喔啉型哌啶化合物的组合物以及治疗或预防疾病的方法，例如疼痛，通过向需要治疗的动物施用一种有效量的取代喹喔啉型哌啶化合物。
• [EN] SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF<br/>[FR] COMPOSÉS DE PIPÉRIDINE DE TYPE QUINOXALINE SUBSTITUÉE ET LEURS UTILISATIONS
  申请人：PURDUE PHARMA LP

  公开号：WO2009027820A3

  公开（公告）日：2009-04-23
• Discovery of Bioavailable 4,4-Disubstituted Piperidines as Potent Ligands of the Chemokine Receptor 5 and Inhibitors of the Human Immunodeficiency Virus-1
  作者：Wieslaw M. Kazmierski、Christopher Aquino、Brian A. Chauder、Felix Deanda、Robert Ferris、Deborah K. Jones-Hertzog、Terrence Kenakin、Cecilia S. Koble、Christian Watson、Pat Wheelan、Hanbiao Yang、Michael Youngman

  DOI：10.1021/jm800598a

  日期：2008.10.23

  We describe robust chemical approaches toward putative CCR5 scaffolds designed in our laboratories. Evaluation of analogues in the (125)I-[MIP-1 beta] binding and Ba-L-HOS antiviral assays resulted in the discovery of 64 and 68 in the 4,4-disubstitited piperidine class H, both potent CCR5 ligands (pIC(50) = 8.30 and 9.00, respectively) and HIV-1 inhibitors (pIC(50) = 7.80 and 7.84, respectively, in Ba-L-HOS assay). In addition, 64 and 68 were bioavailable in rodents, establishing them as lead molecules for further optimization toward CCR5 clinical candidates.
• US8846929B2
  申请人：——

  公开号：US8846929B2

  公开（公告）日：2014-09-30